CYTOF
Altamira Therapeutics Ltd.
Price Chart
Latest Quote
$0.11
+0.05 (+78.33%)
Current Price
| Previous Close | $0.06 |
| Open | $0.06 |
| Day High | $0.11 |
| Day Low | $0.06 |
| Volume | 19,014 |
Stock Information
| Shares Outstanding | 5.72M |
| Total Debt | $790K |
| Cash Equivalents | $4K |
| Net Income | $-5.65M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $612K |
| EPS (TTM) | $-1.19 |
| Exchange | OID |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.13M |
| Income | $-5.65M |
| Book/sh | $0.71 |
| Cash/sh | $0.00 |
| Employees | 11 |
Financial Ratios
| Quick Ratio | 0.09 |
| Current Ratio | 0.11 |
| Debt/Eq | 19.39 |
Returns & Margins
| ROA | -45.75% |
| ROE | -108.79% |
Ownership
| Insider Ownership | 18.80% |
| Institutional Ownership | 4.00% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | 0.15 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.08 |
| SMA50 | $0.08 |
| SMA200 | $0.08 |
| RSI | 76.06 |
| ATR | 0.0079 |
| Shares Float | 4.12M |
| Short Float | 1.35% |
| Short Ratio | 0.52 |
| Volatility | 2.84 |
| Rel Volume | 4.01 |
Performance History
| Week | +50.70% |
| Month | +114.00% |
| Quarter | +48.61% |
| 6 Months | +42.67% |
| YTD | +12.63% |
| Year | +7.00% |
| 3 Years | -99.30% |
| 5 Years | -99.99% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.11 | 19,014 |
| 2026-06-17 | $0.10 | 1,200 |
| 2026-06-16 | $0.06 | 2,100 |
| 2026-06-15 | $0.07 | 0 |
| 2026-06-12 | $0.07 | 0 |
| 2026-06-11 | $0.07 | 0 |
| 2026-06-10 | $0.07 | 10,100 |
| 2026-06-09 | $0.08 | 13,300 |
| 2026-06-08 | $0.08 | 0 |
| 2026-06-05 | $0.08 | 0 |
| 2026-06-04 | $0.08 | 0 |
| 2026-06-03 | $0.08 | 1,100 |
| 2026-06-02 | $0.08 | 6,000 |
| 2026-06-01 | $0.07 | 0 |
| 2026-05-29 | $0.07 | 16,200 |
| 2026-05-28 | $0.06 | 800 |
| 2026-05-27 | $0.11 | 0 |
| 2026-05-26 | $0.11 | 0 |
| 2026-05-22 | $0.11 | 0 |
| 2026-05-21 | $0.11 | 25,000 |
| 2026-05-20 | $0.10 | 100 |
| 2026-05-19 | $0.05 | 300 |
About Altamira Therapeutics Ltd.
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland, Australia, the United States, and Europe. The company develops and supplies peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues through xPhore platform; and offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens It is also developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; and AM-125 that is in post phase II clinical trial for the intranasal treatment of vertigo. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.
đ° Latest News
No news articles available at the moment. Check back later for updates on CYTOF.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Reconciled Cost Of Revenue | - | $268,935 | $1,557,321 | $2,400,086 |
| Cost Of Revenue | - | $268,935 | $1,557,321 | $2,451,104 |
| Expenses | ||||
| Interest Expense | $19,803 | $1,149,075 | $946,958 | $15,438 |
| Total Expenses | $6,921,740 | $6,601,112 | $18,862,743 | $7,517,066 |
| Rent Expense Supplemental | $55,316 | $17,479 | $6,284 | $57,193 |
| Other Income Expense | $-1,519,532 | $-677,513 | $151,239 | $57,156 |
| Other Non Operating Income Expenses | $70,826 | $16,694 | - | - |
| Net Non Operating Interest Income Expense | $-16,476 | $-812,682 | $-827,306 | $14,088 |
| Interest Expense Non Operating | $19,803 | $1,149,075 | $946,958 | $15,438 |
| Operating Expense | $6,921,740 | $6,601,112 | $18,862,743 | $7,517,066 |
| Other Operating Expenses | $-4,466 | $-267,768 | $-9,766 | $-504,004 |
| General And Administrative Expense | $3,067,817 | $3,343,611 | $3,434,218 | $3,980,327 |
| Total Other Finance Cost | - | $10,971 | $1,226 | - |
| Selling And Marketing Expense | - | $73,374 | $2,568,527 | $1,639,009 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-8,457,748 | $-8,091,307 | $-19,530,518 | $-7,316,794 |
| Net Interest Income | $-16,476 | $-812,682 | $-827,306 | $14,088 |
| Interest Income | $3,327 | $336,393 | $119,652 | $29,526 |
| Normalized Income | $-7,640,763 | $-7,441,125 | $-19,681,693 | $-7,372,959 |
| Net Income From Continuing And Discontinued Operation | $-8,457,748 | $-4,306,260 | $-27,778,443 | $-18,661,463 |
| Total Operating Income As Reported | $-6,850,914 | $-6,584,418 | $-18,862,743 | $-7,517,066 |
| Net Income Common Stockholders | $-8,457,748 | $-4,306,260 | $-27,778,443 | $-18,661,463 |
| Net Income | $-8,457,748 | $-4,306,260 | $-27,778,443 | $-18,661,463 |
| Net Income Including Noncontrolling Interests | $-8,457,748 | $-4,306,260 | $-27,778,443 | $-18,661,463 |
| Net Income Discontinuous Operations | $0 | $3,785,047 | $-8,247,925 | $-11,344,669 |
| Net Income Continuous Operations | $-8,457,748 | $-8,091,307 | $-19,530,518 | $-7,316,794 |
| Pretax Income | $-8,457,748 | $-8,091,307 | $-19,538,810 | $-7,445,822 |
| Special Income Charges | $-240,399 | $0 | $-1,191 | $0 |
| Earnings From Equity Interest | $-773,373 | $-44,025 | $0 | $0 |
| Interest Income Non Operating | $3,327 | $336,393 | $119,652 | $29,526 |
| Operating Income | $-6,921,740 | $-6,601,112 | $-18,862,743 | $-7,517,066 |
| Depreciation Amortization Depletion Income Statement | $127,054 | $132,781 | $124,489 | $32,515 |
| Depreciation And Amortization In Income Statement | $127,054 | $132,781 | $124,489 | $32,515 |
| Depreciation Income Statement | $127,054 | $132,781 | $124,489 | $32,515 |
| Gross Profit | - | $-80,572 | $-1,227,688 | $-2,381,219 |
| Per Share | ||||
| Diluted EPS | $-2.99 | $-16.47 | $-428.90 | $-563.52 |
| Basic EPS | $-2.99 | $-16.47 | $-428.90 | $-563.52 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $64 | $990 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-7,493,906 | $-6,159,269 | $-18,618,602 | $-7,404,007 |
| Total Unusual Items | $-816,985 | $-650,182 | $151,239 | $57,156 |
| Total Unusual Items Excluding Goodwill | $-816,985 | $-650,182 | $151,239 | $57,156 |
| Reconciled Depreciation | $127,054 | $132,781 | $124,489 | $83,532 |
| EBITDA (Bullshit earnings) | $-8,310,891 | $-6,809,451 | $-18,467,363 | $-7,346,852 |
| EBIT | $-8,437,945 | $-6,942,232 | $-18,591,852 | $-7,430,384 |
| Diluted Average Shares | $2,832,299 | $491,258 | $45,536 | $33,116 |
| Basic Average Shares | $2,832,299 | $491,258 | $45,536 | $33,116 |
| Diluted NI Availto Com Stockholders | $-8,457,748 | $-4,306,260 | $-27,778,443 | $-18,661,463 |
| Tax Provision | $0 | $0 | $-8,292 | $-129,029 |
| Restructuring And Mergern Acquisition | $240,399 | $0 | $1,191 | $0 |
| Gain On Sale Of Security | $-576,586 | $-650,182 | $152,430 | $57,156 |
| Other Taxes | $4,330 | $14,176 | $3,257 | $772 |
| Research And Development | $3,727,005 | $3,378,312 | $15,310,545 | $3,503,451 |
| Selling General And Administration | $3,067,817 | $3,343,611 | $3,434,218 | $3,980,327 |
| Other Gand A | $2,183,485 | $2,596,063 | $2,752,397 | $2,422,723 |
| Rent And Landing Fees | $55,316 | $17,479 | $6,284 | $57,193 |
| Salaries And Wages | $829,016 | $730,069 | $675,537 | $1,500,411 |
| Other Special Charges | - | $229,175 | - | - |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $1,938,034 | $3,048,171 | $-13,196,943 | $-1,398,781 |
| Total Assets | $8,652,136 | $9,143,504 | $6,813,063 | $20,971,798 |
| Total Non Current Assets | $7,111,657 | $7,689,964 | $4,900,845 | $16,495,676 |
| Investmentin Financial Assets | $103,345 | $95,070 | $209,991 | $217,815 |
| Goodwill And Other Intangible Assets | $4,627,072 | $4,627,072 | $4,208,930 | $15,660,078 |
| Other Intangible Assets | $4,627,072 | $4,627,072 | $4,208,930 | $15,660,078 |
| Current Assets | $1,540,479 | $1,453,540 | $1,912,218 | $4,476,123 |
| Hedging Assets Current | $0 | $293,630 | $292,051 | $0 |
| Prepaid Assets | $190,524 | $337,293 | $766,691 | $1,723,144 |
| Inventory | $0 | $0 | $12,587 | $918,084 |
| Receivables | $351,331 | $88,917 | $824,248 | $758,217 |
| Taxes Receivable | $0 | $26,187 | $810,288 | $438,302 |
| Accounts Receivable | $0 | $0 | $7,053 | $23,790 |
| Cash Cash Equivalents And Short Term Investments | $998,624 | $733,701 | $16,641 | $1,076,678 |
| Cash And Cash Equivalents | $998,624 | $733,701 | $16,641 | $1,076,678 |
| Cash Financial | $998,624 | $733,701 | $16,641 | $1,076,678 |
| Other Current Assets | - | $-1 | - | - |
| Other Receivables | - | $62,730 | $817,195 | $296,125 |
| Other Non Current Assets | - | - | $181 | - |
| Debt | ||||
| Total Debt | $361,053 | $118,430 | $6,843,890 | $629,839 |
| Long Term Debt And Capital Lease Obligation | $238,691 | $0 | $371,451 | $504,852 |
| Current Debt And Capital Lease Obligation | $122,362 | $118,430 | $6,472,439 | $124,987 |
| Current Debt | - | $22,508 | $6,345,041 | - |
| Net Debt | - | - | $6,328,400 | - |
| Other Current Borrowings | - | - | $6,345,041 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,087,030 | $1,468,261 | $15,801,076 | $6,710,502 |
| Total Non Current Liabilities Net Minority Interest | $922,766 | $411,917 | $1,878,614 | $1,393,197 |
| Non Current Deferred Liabilities | $0 | $0 | $1,143,736 | $155,874 |
| Non Current Deferred Taxes Liabilities | $0 | $0 | $136,061 | $155,874 |
| Current Liabilities | $1,164,264 | $1,056,344 | $13,922,462 | $5,317,306 |
| Payables And Accrued Expenses | $832,874 | $711,402 | $7,450,023 | $4,976,896 |
| Payables | $552,049 | $523,367 | $5,312,293 | $4,045,206 |
| Other Payable | $27,200 | $32,445 | $157,974 | $167,749 |
| Accounts Payable | $524,849 | $490,922 | $5,312,293 | $3,877,458 |
| Current Deferred Liabilities | - | $208,892 | - | - |
| Interest Payable | - | $0 | $493,790 | $0 |
| Derivative Product Liabilities | - | - | $0 | $1,349 |
| Equity | ||||
| Common Stock Equity | $6,565,106 | $7,675,243 | $-8,988,013 | $14,261,296 |
| Total Equity Gross Minority Interest | $6,565,106 | $7,675,243 | $-8,988,013 | $14,261,296 |
| Stockholders Equity | $6,565,106 | $7,675,243 | $-8,988,013 | $14,261,296 |
| Gains Losses Not Affecting Retained Earnings | $11,109,165 | $5,129,585 | $84,113 | $67,902 |
| Other Equity Adjustments | $11,109,165 | $5,129,585 | $84,113 | - |
| Retained Earnings | $-3,030,636 | $-21,346,630 | $-226,262,915 | $-192,196,627 |
| Long Term Equity Investment | $1,931,335 | $2,872,623 | $0 | - |
| Other Equity Interest | - | $4,221,617 | $145,532 | - |
| Other | ||||
| Ordinary Shares Number | $4,662,080 | $1,477,785 | $59,002 | $37,410 |
| Share Issued | $4,662,080 | $1,477,785 | $59,002 | $37,410 |
| Tangible Book Value | $1,938,034 | $3,048,171 | $-13,196,943 | $-1,398,781 |
| Invested Capital | $6,565,106 | $7,675,243 | $-2,642,972 | $14,261,296 |
| Working Capital | $376,215 | $397,196 | $-12,010,244 | $-841,183 |
| Capital Lease Obligations | $361,053 | $118,430 | $498,849 | $629,839 |
| Total Capitalization | $6,565,106 | $7,675,243 | $-8,988,013 | $14,261,296 |
| Additional Paid In Capital | $-1,522,747 | $23,889,332 | $216,923,016 | $206,226,317 |
| Capital Stock | $9,324 | $2,956 | $267,773 | $163,705 |
| Common Stock | $9,324 | $2,956 | $267,773 | $163,705 |
| Employee Benefits | $684,075 | $411,917 | $363,427 | $731,122 |
| Non Current Deferred Revenue | $0 | $0 | $1,007,675 | $0 |
| Long Term Capital Lease Obligation | $238,691 | $0 | $371,451 | $504,852 |
| Current Capital Lease Obligation | $122,362 | $118,430 | $127,398 | $124,987 |
| Pensionand Other Post Retirement Benefit Plans Current | $209,028 | $226,512 | $390,984 | $215,422 |
| Current Accrued Expenses | $280,825 | $188,035 | $2,137,730 | $931,690 |
| Investments And Advances | $2,034,680 | $2,967,693 | $209,991 | $217,815 |
| Available For Sale Securities | $103,345 | $95,070 | $209,991 | $217,815 |
| Investmentsin Associatesat Cost | $1,931,335 | $2,872,623 | $0 | - |
| Net PPE | $449,905 | $95,199 | $481,924 | $617,783 |
| Accumulated Depreciation | $-1,065,203 | $-1,016,170 | $-795,376 | $-674,888 |
| Gross PPE | $1,515,108 | $1,111,369 | $1,277,300 | $1,292,670 |
| Other Properties | $489,389 | $420,069 | $382,108 | $386,706 |
| Machinery Furniture Equipment | $257,442 | $277,725 | $252,628 | $255,668 |
| Buildings And Improvements | $768,277 | $413,575 | $642,564 | $650,296 |
| Properties | $0 | $0 | $0 | $0 |
| Duefrom Related Parties Current | $351,331 | $0 | - | - |
| Treasury Shares Number | - | $0 | - | - |
| Foreign Currency Translation Adjustments | - | $177,583 | $132,790 | $67,902 |
| Current Deferred Revenue | - | $208,892 | - | - |
| Finished Goods | - | $130,951 | $12,559 | $918,084 |
| Raw Materials | - | $258,689 | - | - |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-6,216,634 | $-12,811,427 | $-11,336,164 | $-18,596,095 |
| Operating Activities | ||||
| Operating Cash Flow | $-6,113,547 | $-12,811,427 | $-9,092,388 | $-14,957,595 |
| Cash Flow From Continuing Operating Activities | $-6,113,547 | $-12,811,427 | $-9,092,388 | $-14,957,595 |
| Operating Gains Losses | $1,407,892 | $443,208 | $-406,338 | $216,077 |
| Investing Activities | ||||
| Capital Expenditure | $-103,087 | - | $-2,243,776 | $-3,638,499 |
| Investing Cash Flow | $-115,341 | $1,608,090 | $-2,242,761 | $-3,834,434 |
| Cash Flow From Continuing Investing Activities | $-115,341 | $1,608,090 | $-2,242,761 | $-3,834,434 |
| Net Other Investing Changes | - | - | - | $-195,935 |
| Financing Activities | ||||
| Financing Cash Flow | $6,505,166 | $11,821,496 | $10,295,282 | $7,235,230 |
| Cash Flow From Continuing Financing Activities | $6,505,166 | $11,821,496 | $10,295,282 | $7,235,230 |
| Net Other Financing Charges | $-717,589 | $-875,116 | $-37,169 | $-171,553 |
| Cash Dividends Paid | $0 | $0 | $0 | $0 |
| Issuance Of Capital Stock | - | $1,190,561 | - | - |
| Net Common Stock Issuance | - | $1,190,561 | - | - |
| Common Stock Issuance | - | $1,190,561 | - | - |
| Other | ||||
| Repayment Of Debt | $-137,762 | $-1,614,887 | $-119,635 | $-75,156 |
| Issuance Of Debt | $0 | $2,782,415 | $6,323,170 | $0 |
| End Cash Position | $998,624 | $733,701 | $16,641 | $1,076,678 |
| Beginning Cash Position | $733,701 | $16,641 | $1,080,341 | $12,316,891 |
| Effect Of Exchange Rate Changes | $-11,355 | $98,901 | $-23,833 | $316,586 |
| Changes In Cash | $276,278 | $618,159 | $-1,039,867 | $-11,556,799 |
| Interest Paid Cff | $-11,692 | $-165,099 | $-20,422 | $-4,047 |
| Proceeds From Stock Option Exercised | $7,372,209 | $11,694,183 | $4,149,338 | $7,485,986 |
| Net Issuance Payments Of Debt | $-137,762 | $1,167,528 | $6,203,535 | $-75,156 |
| Net Short Term Debt Issuance | $0 | $1,295,979 | $6,323,170 | $-54,699 |
| Short Term Debt Payments | $0 | $-1,486,436 | $0 | $-54,699 |
| Short Term Debt Issuance | $0 | $2,782,415 | $6,323,170 | $0 |
| Net Long Term Debt Issuance | $-137,762 | $-128,451 | $-119,635 | $-20,457 |
| Long Term Debt Payments | $-137,762 | $-128,451 | $-119,635 | $-20,457 |
| Interest Received Cfi | $3,326 | $562 | $1,015 | $0 |
| Net Investment Purchase And Sale | $-15,688 | $11,174 | $0 | $-195,935 |
| Net Business Purchase And Sale | $108 | $1,596,354 | $0 | $0 |
| Sale Of Business | $108 | $2,141,707 | $0 | $0 |
| Purchase Of Business | $0 | $-545,353 | $0 | $0 |
| Net Intangibles Purchase And Sale | $0 | $0 | $-2,243,776 | $-3,638,499 |
| Purchase Of Intangibles | $0 | $0 | $-2,243,776 | $-3,638,499 |
| Net PPE Purchase And Sale | $-103,087 | $0 | $0 | $0 |
| Purchase Of PPE | $-103,087 | $0 | $0 | $0 |
| Change In Working Capital | $28,373 | $-4,720,244 | $3,727,477 | $196,244 |
| Change In Payables And Accrued Expense | $164,754 | $-4,599,211 | $2,072,603 | $2,905,879 |
| Change In Accrued Expense | $101,475 | $-926,779 | $749,885 | $-307,138 |
| Change In Payable | $63,279 | $-3,672,432 | $1,322,718 | $3,213,017 |
| Change In Prepaid Assets | $140,937 | $219,266 | $896,784 | $-1,419,469 |
| Change In Inventory | $0 | $-355,950 | $866,573 | $-918,084 |
| Change In Receivables | $-277,318 | $15,651 | $-108,483 | $-372,081 |
| Other Non Cash Items | $248,801 | $-4,672,060 | $1,910,983 | $191,000 |
| Stock Based Compensation | $532,081 | $422,274 | $358,952 | $1,319,662 |
| Asset Impairment Charge | $0 | $0 | $12,981,307 | $1,673,700 |
| Deferred Tax | $0 | $-111,126 | $-10,815 | $23,652 |
| Deferred Income Tax | $0 | $-111,126 | $-10,815 | $23,652 |
| Depreciation Amortization Depletion | $127,054 | $132,781 | $124,489 | $83,532 |
| Depreciation And Amortization | $127,054 | $132,781 | $124,489 | $83,532 |
| Depreciation | $127,054 | $132,781 | $124,489 | $83,532 |
| Pension And Employee Benefit Expense | $61,127 | $46,283 | $114,308 | $72,122 |
| Earnings Losses From Equity Investments | $773,373 | $44,025 | $0 | $0 |
| Net Foreign Currency Exchange Gain Loss | $573,392 | $200,722 | $-48,258 | $-305,578 |
| Net Income From Continuing Operations | $-8,457,748 | $-4,306,260 | $-27,778,443 | $-18,661,463 |
| Sale Of Investment | - | $11,953 | $0 | - |
| Gain Loss On Investment Securities | - | $152,178 | $-472,388 | $449,533 |
| Long Term Debt Issuance | - | - | - | $0 |
| Purchase Of Investment | - | - | - | $-195,935 |
Fetched: 2026-02-02